Targeted trans -splicing of highly abundant transcripts for...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S183000, C435S320100, C435S325000, C536S023200, C530S350000

Reexamination Certificate

active

07871795

ABSTRACT:
The present invention provides methods and compositions for generating novel nucleic acid molecules through RNA trans-splicing that target a highly expressed pre-mRNA and contain the coding sequence of a protein or polypeptide of interest. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with the target precursor messenger RNA molecule (target pre-mRNA) that is abundantly expressed, and mediate a trans-splicing reaction resulting in the generation of novel chimeric RNA molecule (chimeric RNA) capable of encoding a protein or polypeptide of interest. The invention provides for the in vivo production of chimeric RNA molecules that encode and result in the production of a protein or polypeptide of interest.

REFERENCES:
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5589377 (1996-12-01), Lebkowski et al.
patent: 5616326 (1997-04-01), Spibey
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5700470 (1997-12-01), Saito et al.
patent: 5731172 (1998-03-01), Saito et al.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5756283 (1998-05-01), Wilson et al.
patent: 5789390 (1998-08-01), Descamps et al.
patent: 5820868 (1998-10-01), Mittal et al.
patent: 5837484 (1998-11-01), Trempe et al.
patent: 5843742 (1998-12-01), Natsoulis et al.
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5869037 (1999-02-01), Crystal et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5885808 (1999-03-01), Spooner et al.
patent: 5891690 (1999-04-01), Massie
patent: 5919676 (1999-07-01), Graham et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5928944 (1999-07-01), Seth et al.
patent: 5932210 (1999-08-01), Gregory et al.
patent: 5952221 (1999-09-01), Kurtzman et al.
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5962313 (1999-10-01), Podsakoff et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6013487 (2000-01-01), Mitchell
patent: 6083702 (2000-07-01), Mitchell et al.
patent: 6280978 (2001-08-01), Mitchell et al.
patent: 7094399 (2006-08-01), Otto
patent: 7399753 (2008-07-01), Mitchell
patent: 2006/0094110 (2006-05-01), McGarrity
patent: 2006/0134658 (2006-06-01), Garcia-Blanco
patent: 2006/0154257 (2006-07-01), Mitchell
patent: 2006/0160182 (2006-07-01), McGarrity
patent: 2006/0177933 (2006-08-01), Puttaraju
patent: 2006/0194317 (2006-08-01), Puttaraju
patent: 2006/0234247 (2006-10-01), Puttaraju
patent: 2006/0246422 (2006-11-01), Mitchell
patent: WO 88/09810 (1988-12-01), None
patent: WO 89/10134 (1989-11-01), None
patent: WO 98/11241 (1998-03-01), None
patent: WO 00/09734 (2000-02-01), None
U.S. Appl. No. 10/693,192, filed Oct. 23, 2003, “Screening Method for Identification of Efficient Pre-Trans-Splicing Molecules,” Mitchell et al.
U.S. Appl. No. 10/434,727, filed May 8, 2003, “Use of Sliceosome Mediated RNA Trans-Splicing to Confer Cell Selective Replication to Adenoviruses,” Otto et al.
U.S. Appl. No. 10/374,784, filed Feb. 25, 2003, “Trans-Splicing Mediated Imaging of Gene Expression,” Mitchell et al.
U.S. Appl. No. 10/360,787, filed Jun. 5, 2002, “Spliceosome Mediated RNA Trans-Splicing for Correction of Factor VIII Genetic Defects,” Mitchell et al.
U.S. Appl. No. 10/198,447, filed Jul. 17, 2002, “Spliceosome Mediated RNA Trans-Splicing for Correction of Skin Disorders,” Mitchell et al.
U.S. Appl. No. 10/136,723, filed Apr. 30, 2002, “Transgenic Animal Model for Spliceosome-mediated RNA Trans-Splicing,” Puttaraju et al.
U.S. Appl. No. 10/103,294, filed Mar. 20, 2002, “Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
U.S. Appl. No. 10/075,028, filed Feb. 12, 2002, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
U.S. Appl. No. 10/076,248, filed Feb. 12, 2002, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
U.S. Appl. No. 09/838,858, filed Apr. 20, 2001, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mansfield et al.
U.S. Appl. No. 09/756,097, filed Jan. 8, 2001, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
U.S. Appl. No. 09/756,095, filed Jan. 8, 2001, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
U.S. Appl. No. 09/756,096, filed Jan. 8, 2001, “Methods and Compositions for Use in Spliceosome Mediated RNA Trans-Splicing,” Mitchell et al.
Bhaumik et al., “Molecular Imaging of Gene Expression in Living Subjects by Splicesome-Mediated RNA Trans-Splicing,” Jun. 8, 2004, Proc. Natl. Acad. Sci., 101:23:8693-8698.
Tahara et al., “Trans-Splicing Repair of CD40-Ligand Deficiency Results in Naturally Regulated Correction of A Mouse Model of Hyper-IgM X-Linked Immunodeficiency,” Aug. 2004, Nature Medicine, 10:835-841.
Chao et al., “Phenotype Correction of Hemophilia A Mice by Spliceosome-Mediated RNA Trans-Splicing,” Aug. 2003, Nature Medicine, 9:1-5.
Liu et al., “Partial Correction of Endogenous Δ508 CFTR in Human Cystic Fibrosis Airway Epithelia by Spliceosome-Mediated RNA Trans-Splicing,” Jan. 2002, Nature Biotechnology, 20:47-52.
Kim et al., “Role of the Nonsense-Mediated Decay Factor hUpf3 in the Splicing Dependent Exon-Exon Junction Complex,” Sep. 7, 2001, Science 293:1832-1836.
Kirn et al., “Replication-Selective Virotherapy for Cancer:Biological Principles, Risk Management and Future Directions,” Jul. 2001, Nat. Med. 7:781-787.
Tian et al., “Strong RNA Splicing Enhancers Identified by a Modified Method of Cycled Selection Interact with SR Protein,” Sep. 7, 2001, J. Biological Chemistry 276:33833-33839.
Mansfield et al., “Repair of CFTR mRNA by Splicesome-Mediated RNA Trans-Splicing,” Jul. 28, 2000, Gene Therapy 7:1885-1895.
Tacke et al., “Determinants of SR Protein Specificity,” 1999, Curr. Opin. Cell Biol. 11:358-362.
He et al. “A Simplified System for Generating Recombinant Adenoviruses,” Mar. 1998, Proc. Natl. Acad. Sci., 95, 2509-2514.
Lan et al., “Ribozyme-Mediated Repair of Sickle β-Globin mRNAs in Erythrocyte Precursors” Jun. 5, 1998, Science 280:1593-1596.
Phylactou et al., “Ribozyme-Mediated Trans-Splicing of a Trinucleotide Repeat” Apr. 1998, Nature Genetics 18:378-381.
Staley et al., “Mechanical Devices of the Spliceosome: Motors, Clocks, Springs and Things,” 1998, Cell 92:315-326.
Bellet et al., “Malignant Transformation of Nontrophoblastic Cells is Associated With the Expression of Chorionic Gonadotropin β Genes Normally Transcribed Introphoblastic Cells,” Feb. 1, 1997, Cancer Res. 57:516-523.
Coolidge et al., “Functional Analysis of The Polypyrimidine Tract in Pre-mRNA Splicing,” 1997, Nucleic Acids Res. 25:888-896.
Crouzet et al. “Recombinational Construction inEscherichia coliof Infectious Adenoviral Genomes,” Feb. 1997, Proc. Natl. Acad. Sci., 94, 1414-1419.
Good et al., “Expression of Small, Therapeutic RNAs in Human Cell Nuclei,” 1997, Gene Ther. 4:45-54.
Malek et al., “Evolution of Trans-Splicing Plant Mitochondrial Introns in Pre-Permian Times,” Jan. 1997, Proc. Nat'l. Acad. Sci., 94:553-558.
Chartier, et al., “Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination inEscherichia coli,” Jul. 1996, Virol. 70, 4805-4810.
Hoon et al., “Detection of Metastatic Breast Cancer by β-hCG Polymerase Chain Reaction,” 1996, Int J. Cancer 69:369-374.
Jones et al., “Tagging Ribozyme Reaction Sites to Follow Trans-Splicing in Mammalian Cells,” Jun. 1996, Nature Medicine 2:643-64

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Targeted trans -splicing of highly abundant transcripts for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted trans -splicing of highly abundant transcripts for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted trans -splicing of highly abundant transcripts for... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2729485

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.